control virus, 105535-AAV8, Dpp4 GFP ) or AAV8.TBG.PI.CRE.rBG (AAV-Cre
Among these, dysglycemia is an important predisposing factor: studies have shown that chronic inhibition of cerebral energy metabolism, especially reduced glucose utilization, can induce epileptic seizures ( 4.2 Epilepsy and alcoholism 4.2.1 New-onset epilepsy and alcoholism Acute symptomatic seizures were attributed to acute alcoholism in 2.9% (3/102) of the adults who presented for the first time in the emergency department in five Latin American countries ( 4.2.2 Epilepsy and alcohol withdrawal Alcohol withdrawal was found to be the most common cause of acute symptomatic seizures (74.1%) ( 4.2.3 Epilepsy and alcohol dependence A study of Polish prisoners revealed that alcohol-dependent prisoners were four times more likely to develop epilepsy than were those without this condition and that alcohol dependence was strongly associated with epilepsy, independent of other variables ( 4.2.4 Alcoholic encephalopathy with epilepsy In a retrospective analysis of 34 patients with subacute encephalopathy with alcoholic epileptic syndrome, abstaining from alcohol was the cause in 35.2% of patients, excessive alcohol consumption was the cause in 11.7% of patients, 41.1% of patients had a history of seizures in the context of alcohol withdrawal syndrome, 85.2% of patients had a partial periodic discharge observed on an EEG, and 64.7% of patients had a high signal area and limited diffusion in neuroimaging ( 4.3 Epilepsy and uremia 4.3.1 Association of uremia with seizures Patients with end-stage renal disease who underwent dialysis had a greater prevalence of epilepsy (8.8%), and the risk of death in patients diagnosed with epilepsy was 1.11 times greater than that in patients without epilepsy ( 4.3.2 Clinical characteristics of epilepsy caused by uremia In a study of maintenance hemodialysis patients, new-onset epilepsy was often severe and progressed rapidly, and the mortality rate was high (45.71%, 16/35)
Anti-obesity drugs, such as liraglutide, orlistat and semaglutide are also used off-label
For the new study, researchers analyzed data on nearly 1.8 million patients with type 2 diabetes, of whom about 28% had been prescribed a GLP-1 drug
